Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- Resource Type
- Article
- Source
- Targeted Oncology; 2020, Vol. 15 Issue 6, p733-741, 9p
- Subject
- Language
- ISSN
- 17762596